Previous 10 | Next 10 |
2023-09-05 23:24:03 ET Summary Q2 2023 earnings showcasted robust performance and raised forecast for 2023 non-GAAP adjusted cash receipts. Royalty Pharma enters strategic partnership with Ferring Pharmaceuticals, investing $300 million upfront for royalties on bladder cancer drug...
• P roceeds to support continued development and commercialization of Endocrine Rare Disease products and general corporate purposes NEW YORK and COPENHAGEN, Denmark, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: ASND) today...
- Proceeds to support continued development and commercialization of Endocrine Rare Disease products, and general corporate purposes COPENHAGEN, Denmark and NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) and Royalty Pharma plc (Nasdaq: RPRX) today announce...
Royalty Pharma to pay Ferring $300 million upfront and a potential $200 million milestone payment in exchange for royalties on the sales of Ferring’s intravesical gene therapy Adstiladrin ® (nadofaragene firadenovec-vncg) Transaction provides Ferring with significant non...
2023-08-24 05:27:43 ET More on Royalty Pharma Royalty Pharma: Not Quite In The 'Buy Zone' Yet Royalty Pharma: A Strong Start To 2023 Bodes Well For The Future Royalty Pharma gains as CEO buy over $7M company shares Royalty Pharma launches $1B share repurchase...
Ad hoc announcement pursuant to Art. 53 LR Royalty Pharma to pay Ferring $300 million upfront and a potential $200 million milestone payment in exchange for royalties on the sales of Ferring’s intravesical gene therapy Adstiladrin ® (nadofaragene firadenovec-vncg) ...
2023-08-08 13:35:06 ET Royalty Pharma plc (RPRX) Q2 2023 Earnings Conference Call August 8, 2023 8:00 am ET Company Participants Pablo Legorreta - Chief Executive Officer Marshall Urist - Executive Vice President, Head of Research and Investment Terrance Coyne - ...
2023-08-08 07:09:47 ET Royalty Pharma press release ( NASDAQ: RPRX ): Q2 consolidated net income of $351M. Revenue of $538M (+0.4% Y/Y) beats by $1.41M . Adjusted Cash Receipts increased 4% to $545 million, driven by strong portfolio performance and new royalt...
Net cash provided by operating activities (GAAP) of $608 million and Adjusted Cash Receipts ( 1) (non-GAAP) of $545 million Announced transactions of up to $1.7 billion year-to-date, including $659 million in upfront payments Raising 2023 guidance: Adjusted Cas...
2023-08-07 13:38:01 ET Royalty Pharma ( NASDAQ: RPRX ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, before market open. The consensus EPS Estimate is $0.81 and the consensus Revenue Estimate is $536.59M. Over the last 3 months, EPS estimates hav...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on September 13, 2024, to shareholders of record at the...